Explore the most significant advancements in modern pharmacology through this selection of drugs derived from marine organisms. Discover how bioactive compounds from sponges, tunicates, and other ocean inhabitants are revolutionising treatments, especially in areas like oncology. This list highlights marine natural products that have reached clinical trials or approval, showcasing their potential in medicine. Dive into the fascinating world of marine bioprospecting and its contributions to global health.
Kills cancer cells by blocking DNA polymerase function
(+4)
Cytarabine is a crucial antineoplastic drug that originated from a marine sponge, showcasing the potential of marine biodiversity in drug discovery. Its ability to block DNA polymerase function makes it an effective treatment against various leukemias. This medication represents a milestone in pharmacology derived from marine organisms.
First marine anticancer drug approved for clinical use
(+3)
Yondelis is an innovative oncological drug derived from a marine organism, specifically the tunicate Ecteinascidia turbinata. Its unique mechanism of action, binding to DNA and affecting transcription and repair, makes it a valuable therapeutic option for soft tissue sarcomas and ovarian cancer.
Approved for metastatic breast cancer treatment
(+2)
Eribulin is an effective antineoplastic drug for the treatment of metastatic breast cancer, notable for being a synthetic derivative of the Japanese marine sponge Halichondria okadai. Its marine origin provides a unique mechanism of action, interfering with microtubular growth to induce apoptosis in cancer cells.
Active against herpes simplex virus
(+3)
Vidarabine (Ara-A) is a pioneering antiviral drug, derived from the marine sponge <i>Tectitethya crypta</i>, which marked a milestone as one of the first marine compounds to reach clinical trials. Its mechanism of action inhibits viral DNA synthesis, proving effective against viruses such as herpes, vaccinia, and varicella zoster, thus demonstrating its therapeutic value.
Potentially effective and safe for solid tumors
(+4)
Aplidin is an innovative antitumor drug derived from a marine organism, specifically a sea tunicate. It has shown promising cytotoxic activity against a variety of solid tumors and hematological malignancies, including multiple myeloma, with positive results in Phase III clinical trials.
All the rankings you can imagine
Thousands of verified votes to discover the best. Your vote here counts
PM60184 is an investigational drug being evaluated for its efficacy in treating advanced or metastatic colorectal cancer. Its development and study in clinical trials, such as NCT03427268, demonstrate its relevance as a promising marine organism-derived therapy to combat this disease.
Exhibits anticancer effects in BTC cells
(+4)
Fadraciclib is an investigational oncology drug demonstrating a novel mechanism of action as a dual CDK2/9 inhibitor. Its development represents a significant advancement in precision medicine for treating various cancers, including advanced solid tumors and lymphomas. It has shown preclinical antitumor activity and signs of efficacy in clinical trials, underscoring its therapeutic potential.
Overcomes limitations of current HO-1 inhibitors
(+4)
This drug stands out for its ability to enhance the effectiveness of immune cells and chemotherapy treatments, even in resistant tumors. Its at-home oral administration between chemotherapy sessions represents a significant improvement in patient convenience and accessibility.
Superior efficacy over pembrolizumab
(+4)
Ivonescimab is an innovative drug that has demonstrated superior efficacy in the treatment of non-small cell lung cancer, outperforming existing therapies in Phase III trials. Its bispecific mechanism of action, combining immunotherapy and anti-angiogenesis, positions it as a significant advance in oncology. This drug offers new hope for lung cancer patients, including chemo-free treatment options.
Potential to provide clinically meaningful benefit for CFTR mutations
(+2)
Alyftrek is an innovative drug for cystic fibrosis that incorporates components derived from research into marine organisms, highlighting its relevance in the field of marine biotechnology. Its development and approval mark a significant advance in the treatment of this disease, offering a triple combination therapy that improves CFTR function.
Our methodology for ranking the best marine organism-derived drugs focuses on clinical relevance and regulatory approval. We aim to highlight compounds that have achieved significant impact in medicine, especially in areas like oncology.